Last $340.79 USD
Change Today -0.72 / -0.21%
Volume 448.9K
As of 5:20 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

regeneron pharmaceuticals (REGN) Snapshot

Open
$342.10
Previous Close
$341.51
Day High
$344.70
Day Low
$339.10
52 Week High
08/18/14 - $353.05
52 Week Low
08/22/13 - $233.06
Market Cap
34.4B
Average Volume 10 Days
501.2K
EPS TTM
$3.58
Shares Outstanding
99.1M
EX-Date
--
P/E TM
95.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for REGENERON PHARMACEUTICALS (REGN)

regeneron pharmaceuticals (REGN) Details

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company’s antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.

regeneron pharmaceuticals (REGN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $3.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $194.2K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $2.6M
Senior Vice President of Research & Developme...
Total Annual Compensation: $863.0K
Senior Vice President of Commercial
Total Annual Compensation: $814.5K
Compensation as of Fiscal Year 2013.

regeneron pharmaceuticals (REGN) Key Developments

Regeneron Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Re-Affirms Capital Expenditures for Full Year of 2014

Regeneron Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue was $665,700,000 against $457,642,000 a year ago. Income from operations was $222,406,000 against $158,103,000 a year ago. Income before income taxes was $203,119,000 against $147,692,000 a year ago. Net income was $92,735,000 against $87,376,000 a year ago. Diluted net income per share was $0.82 against $0.79 a year ago. Non-GAAP net income was $289,365,000 against $197,669,000 a year ago. Non-GAAP net income per share diluted was $2.47 against $1.73 a year ago. For the six months, the company reported total revenue was $1,291,440,000 against $897,306,000 a year ago. Income from operations was $408,345,000 against $311,153,000 a year ago. Income before income taxes was $378,382,000 against $289,523,000 a year ago. Net income was $158,178,000 against $186,250,000 a year ago. Diluted net income per share was $1.40 against $1.69 a year ago. Non-GAAP net income was $551,960,000 against $398,312,000 a year ago. Non-GAAP net income per share diluted was $4.70 against $3.50 a year ago. For the full year of 2014, the company re-affirmed capital expenditures between $350 million - $425 million.

Regeneron Pharmaceuticals, Inc. and Sanofi Plans to Use Priority Review Voucher for Alirocumab U.S. FDA Submission

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the Companies intend to use a U.S. Food and Drug Administration rare pediatric disease priority review voucher in connection with the Biologics License Application submission for alirocumab. The priority review voucher entitles the holder to designate a BLA for priority review, which provides for an expedited 6-month review from the filing date instead of the standard 10-month review. Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals, Inc., purchased the voucher from BioMarin GALNS Ltd., a direct, wholly-owned subsidiary of BioMarin Pharmaceutical, Inc., which had received it through the FDA's Rare Pediatric Disease Priority Review Voucher Program. Sanofi and Regeneron will equally share the purchase price of $67.5 million. Sanofi and Regeneron expect to submit U.S. and EU regulatory submissions for alirocumab before year end. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated for its potential to lower low-density lipoprotein cholesterol (LDL-C) in patients who are not at their current LDL-C target with standard lipid-modifying therapies. The Pediatric PRV was created by the 2012 Food and Drug Administration Safety and Innovation Act and is intended to encourage the development of treatments for rare pediatric diseases. Companies that receive a voucher may use it or transfer the voucher, including by sale, to other organizations.

Sanofi and Regeneron Pharmaceuticals, Inc. Report Positive Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

Sanofi and Regeneron Pharmaceuticals, Inc. announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater % reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo or active comparator. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). The nine trials included ODYSSEY LONG TERM, FH I, FH II, HIGH FH, COMBO I, COMBO II, OPTIONS I, OPTIONS II and ALTERNATIVE. All patients received alirocumab in addition to standard-of-care lipid-lowering therapy, with the exception of some patients in ODYSSEY ALTERNATIVE. The 2,341-patient ongoing ODYSSEY LONG TERM trial evaluated the long-term safety and efficacy of alirocumab compared to placebo. Both treatment groups received statins and some patients also received additional lipid-lowering therapies. The trial met its primary efficacy endpoint at 24 weeks. A pre-specified interim safety analysis was performed when all patients reached one year and approximately 25% of patients reached 18 months of treatment. A lower rate of adjudicated major cardiovascular events (cardiac death, myocardial infarction, stroke, and unstable angina requiring hospitalization) was observed in the alirocumab arm compared to placebo in a post-hoc analysis (p-value of less than 0.05). The potential of alirocumab to demonstrate cardiovascular benefit is being prospectively assessed in an ongoing 18,000-patient ODYSSEY OUTCOMES trial.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REGN:US $340.79 USD -0.72

REGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for REGN.
View Industry Companies
 

Industry Analysis

REGN

Industry Average

Valuation REGN Industry Range
No financial data is available for REGN.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit www.regeneron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.